Aytu BioScience Announces Pricing of $7.5 Million Public Offering of Common …

Aytu BioScience Announces Pricing of $7.5 Million Public Offering of Common …

Aytu's current portfolio of commercial and late-stage urology products addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction, and the company plans to expand into other urological indications for which there

(Visited 3 times, 1 visits today)
6
Like
Save

Comments

Write a comment